Cardiology

Prasugrel and ticagrelor: Equally safe and effective in STEMI

The antiplatelet drugs prasugrel and ticagrelor had similar safety and efficacy among patients with acute myocardial infarction and ST segment elevations (STEMI), according to results of PRAGUE-18, the first randomised, head-to-head ...

Cardiology

Anemia independently linked to high platelet reactivity in PCI

(HealthDay)—Anemia is independently associated with high platelet reactivity (HPR) and is associated with all-cause mortality and major bleeding after percutaneous coronary intervention with drug-eluting stents, according ...

Cardiology

ACC: Faster absorption of crushed prasugrel in STEMI

(HealthDay)—Crushed prasugrel correlates with faster drug absorption for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI), according to a study ...

Health

Medication review at ICU to ward transfer cuts drug problems

(HealthDay)—Medication review by a clinical pharmacist and immediate communication of drug therapy recommendations can reduce the number of drug-related problems (DRPs) at the transfer point from intensive care unit (ICU) ...

Cardiology

Anti-clotting drug approved for angioplasty

(HealthDay)—Kengreal (cangrelor) has been approved by the U.S. Food and Drug Administration to prevent blood clots from forming during angioplasty.

page 6 from 13